ArticleCancers2022

Cost-Effectiveness of Molecularly Guided Treatment in Diffuse Large B-Cell Lymphoma (DLBCL) in Patients under 60.

Dean A Regier et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.